Subscribe To
TYRA / Wall Street Analysts Think Tyra Biosciences, Inc. (TYRA) Could Surge 52.22%: Read This Before Placing a Bet
TYRA News
By Zacks Investment Research
June 7, 2023
Wall Street Analysts Think Tyra Biosciences, Inc. (TYRA) Could Surge 52.22%: Read This Before Placing a Bet
The consensus price target hints at a 52.2% upside potential for Tyra Biosciences, Inc. (TYRA). While empirical research shows that this sought-after more_horizontal
By Seeking Alpha
June 1, 2023
Tyra Biosciences: Early Stage Developer Of Novel FGFR3-Selective Molecules
TYRA has the first FGFR3 inhibitor in the clinic. The company has a large market cap for an early-stage company and a good deal of cash. They do not h more_horizontal
By Zacks Investment Research
May 23, 2023
What Makes Tyra Biosciences, Inc. (TYRA) a Good Fit for 'Trend Investing'
Tyra Biosciences, Inc. (TYRA) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit fr more_horizontal
By Zacks Investment Research
March 27, 2023
Here's Why 'Trend' Investors Would Love Betting on Tyra Biosciences, Inc. (TYRA)
Tyra Biosciences, Inc. (TYRA) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on th more_horizontal
By Zacks Investment Research
March 1, 2023
Should You Buy Tyra Biosciences (TYRA) Ahead of Earnings?
Tyra Biosciences (TYRA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season. more_horizontal
By PRNewsWire
September 8, 2022
Tyra Biosciences to Participate at September 2022 Investor Conferences
CARLSBAD, Calif. , Sept. 8, 2022 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a precision oncology company focused on developing purpose-bui more_horizontal
By PRNewsWire
September 5, 2022
Tyra Biosciences to Present Preclinical Data on TYRA-300, an FGFR3-selective Inhibitor, at ESMO 2022 Congress
CARLSBAD, Calif. , Sept. 5, 2022 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a precision oncology company focused on developing purpose-bui more_horizontal